Gene

RSF1

remodeling and spacing factor 1

Explore in graph →CI-GENE-00029561HGNC:18118 ENSG00000048649 NCBI 51773 CIViC Cancer geneApproved

Curated evidence

Clinical evidence (1)

CIViC items involving this gene, grouped by molecular profile and therapy, with native levels and directions. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
RSF1 Amplification1
Tamoxifen	Malignant Breast Neoplasm	Predictive	B	Supports Resistance	2	accepted	EID857 In retrospective study, 413 patients were assessed for RSF1 amplification. 28 patients with RSF1 amplification did not show a benefit from adjuvant tamoxifen compared to placebo (12 treated vs 16 plac… (full text at CIViC) PMID 24367492 · Keilty et al., 2013 · Open in CIViC	civic

Cohorts

Alteration frequency by cohort (2)

Frequency = cases affected / cases profiled within one cohort. Cohorts are never pooled.

cbioportalObserved2 cohort rows · frequency = affected / profiled, as published by each cohort; cohorts are not pooled. Hover a row badge for its release.

Cohort	Mapped cancer	Alteration	Affected (n)	Profiled (n)	Frequency (%)	Rank in cohort	Source
Breast Invasive Carcinoma (British Columbia, Nature 2012) brca_bccrc	Invasive Breast Carcinoma	Ssm	2	65

Literature

Linked publications (1)

25 per page, newest first.

pubmedPublishedShowing 1–1 of 1 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

RSF1 and not cyclin D1 gene amplification may predict lack of benefit from adjuvant tamoxifen in high-risk pre-menopausal women in the MA.12 randomized clinical trial.
· PLoS One · 2013 · PMID 24367492 · validated civic_curation pubmed